H2N2V1, Istex, Corpus, bibRecord, 001264

Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis

Identifieur interne : 001264 ( Istex/Corpus ); précédent : 001263; suivant : 001265

Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis

Auteurs : Peter F. Wright ; Kon Taik Khaw ; Michael N. Oxman ; Shwachman Harry

Source :

Journal of Infectious Diseases [ 0022-1899 ] ; 1976.

RBID : ISTEX:EF87B5B5A17FF4F98612144AC67755E0B07EB3ED

Abstract

Amantadine·Hel, an antiviral drug clinically effective against most strains of influenza A virus, was evaluated in a double-blind trial in 153 children with cystic fibrosis during the initial appearance of influenza A/ England/ 42 virus in the New England area. Infection with this variant strain of influenza virus did not reach epidemic proportions during the study, so that the effectiveness of amantadine in this study population could not be fully assessed. However, the potential symptomatic and biochemical toxicity of amantadine was carefully monitored in a pediatric population. Serologic screening by complement fixation tests indicated that respiratory viruses may be important pathogens in exacerbations of respiratory disease in patients with cystic fibrosis.

Url:

https://api.istex.fr/ark:/67375/HXZ-1P46HZCW-3/fulltext.pdf

DOI: 10.1093/infdis/134.2.144

Links to Exploration step

ISTEX:EF87B5B5A17FF4F98612144AC67755E0B07EB3ED

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis</title>
<author><name sortKey="Wright, Peter F" sort="Wright, Peter F" uniqKey="Wright P" first="Peter F." last="Wright">Peter F. Wright</name>
<affiliation><mods:affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Please address requests for reprints to Dr. Peter F. Wright, Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, Tennessee 37203.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Khaw, Kon Taik" sort="Khaw, Kon Taik" uniqKey="Khaw K" first="Kon Taik" last="Khaw">Kon Taik Khaw</name>
<affiliation><mods:affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Oxman, Michael N" sort="Oxman, Michael N" uniqKey="Oxman M" first="Michael N." last="Oxman">Michael N. Oxman</name>
<affiliation><mods:affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Harry, Shwachman" sort="Harry, Shwachman" uniqKey="Harry S" first="Shwachman" last="Harry">Shwachman Harry</name>
<affiliation><mods:affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:EF87B5B5A17FF4F98612144AC67755E0B07EB3ED</idno>
<date when="1976" year="1976">1976</date>
<idno type="doi">10.1093/infdis/134.2.144</idno>
<idno type="url">https://api.istex.fr/ark:/67375/HXZ-1P46HZCW-3/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001264</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001264</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis</title>
<author><name sortKey="Wright, Peter F" sort="Wright, Peter F" uniqKey="Wright P" first="Peter F." last="Wright">Peter F. Wright</name>
<affiliation><mods:affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Please address requests for reprints to Dr. Peter F. Wright, Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, Tennessee 37203.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Khaw, Kon Taik" sort="Khaw, Kon Taik" uniqKey="Khaw K" first="Kon Taik" last="Khaw">Kon Taik Khaw</name>
<affiliation><mods:affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Oxman, Michael N" sort="Oxman, Michael N" uniqKey="Oxman M" first="Michael N." last="Oxman">Michael N. Oxman</name>
<affiliation><mods:affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Harry, Shwachman" sort="Harry, Shwachman" uniqKey="Harry S" first="Shwachman" last="Harry">Shwachman Harry</name>
<affiliation><mods:affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Journal of Infectious Diseases</title>
<title level="j" type="abbrev">J Infect Dis.</title>
<idno type="ISSN">0022-1899</idno>
<idno type="eISSN">1537-6613</idno>
<imprint><publisher>The University of Chicago Press</publisher>
<date when="1976-08">1976</date>
<biblScope unit="vol">134</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="144">144</biblScope>
<biblScope unit="page" to="149">149</biblScope>
</imprint>
<idno type="ISSN">0022-1899</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0022-1899</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Amantadine·Hel, an antiviral drug clinically effective against most strains of influenza A virus, was evaluated in a double-blind trial in 153 children with cystic fibrosis during the initial appearance of influenza A/ England/ 42 virus in the New England area. Infection with this variant strain of influenza virus did not reach epidemic proportions during the study, so that the effectiveness of amantadine in this study population could not be fully assessed. However, the potential symptomatic and biochemical toxicity of amantadine was carefully monitored in a pediatric population. Serologic screening by complement fixation tests indicated that respiratory viruses may be important pathogens in exacerbations of respiratory disease in patients with cystic fibrosis.</div>
</front>
</TEI>
<istex><corpusName>oup</corpusName>
<keywords><teeft><json:string>amantadine</json:string>
<json:string>cystic</json:string>
<json:string>cystic fibrosis</json:string>
<json:string>placebo</json:string>
<json:string>respiratory illness</json:string>
<json:string>serologic</json:string>
<json:string>influenza virus</json:string>
<json:string>influenza</json:string>
<json:string>toxicity</json:string>
<json:string>serologic evidence</json:string>
<json:string>viral</json:string>
<json:string>syncytial</json:string>
<json:string>infectious disease</json:string>
<json:string>respiratory syncytial virus</json:string>
<json:string>illness score</json:string>
<json:string>influenza virus infection</json:string>
<json:string>amantadine level</json:string>
<json:string>major episode</json:string>
<json:string>viral infection</json:string>
<json:string>datum</json:string>
<json:string>hospital medical center</json:string>
<json:string>antiviral drug</json:string>
<json:string>disease control</json:string>
<json:string>alkaline phosphatase</json:string>
<json:string>placebo influenza virus type</json:string>
<json:string>antibody titer</json:string>
<json:string>virus infection</json:string>
<json:string>national institute</json:string>
<json:string>virus</json:string>
<json:string>exacerbation</json:string>
</teeft>
</keywords>
<author><json:item><name>Peter F. Wright</name>
<affiliations><json:string>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</json:string>
<json:string>Please address requests for reprints to Dr. Peter F. Wright, Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, Tennessee 37203.</json:string>
</affiliations>
</json:item>
<json:item><name>Kon Taik Khaw</name>
<affiliations><json:string>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</json:string>
</affiliations>
</json:item>
<json:item><name>Michael N. Oxman</name>
<affiliations><json:string>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</json:string>
</affiliations>
</json:item>
<json:item><name>Shwachman Harry</name>
<affiliations><json:string>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</json:string>
</affiliations>
</json:item>
</author>
<arkIstex>ark:/67375/HXZ-1P46HZCW-3</arkIstex>
<language><json:string>unknown</json:string>
</language>
<originalGenre><json:string>research-article</json:string>
</originalGenre>
<abstract>Amantadine·Hel, an antiviral drug clinically effective against most strains of influenza A virus, was evaluated in a double-blind trial in 153 children with cystic fibrosis during the initial appearance of influenza A/ England/ 42 virus in the New England area. Infection with this variant strain of influenza virus did not reach epidemic proportions during the study, so that the effectiveness of amantadine in this study population could not be fully assessed. However, the potential symptomatic and biochemical toxicity of amantadine was carefully monitored in a pediatric population. Serologic screening by complement fixation tests indicated that respiratory viruses may be important pathogens in exacerbations of respiratory disease in patients with cystic fibrosis.</abstract>
<qualityIndicators><score>4.923</score>
<pdfWordCount>2924</pdfWordCount>
<pdfCharCount>18624</pdfCharCount>
<pdfVersion>1.4</pdfVersion>
<pdfPageCount>6</pdfPageCount>
<pdfPageSize>612 x 768.96 pts</pdfPageSize>
<pdfWordsPerPage>487</pdfWordsPerPage>
<pdfText>true</pdfText>
<refBibsNative>false</refBibsNative>
<abstractWordCount>111</abstractWordCount>
<abstractCharCount>772</abstractCharCount>
<keywordCount>0</keywordCount>
</qualityIndicators>
<title>Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis</title>
<pmid><json:string>787443</json:string>
</pmid>
<genre><json:string>research-article</json:string>
</genre>
<host><title>Journal of Infectious Diseases</title>
<language><json:string>unknown</json:string>
</language>
<issn><json:string>0022-1899</json:string>
</issn>
<eissn><json:string>1537-6613</json:string>
</eissn>
<publisherId><json:string>jid</json:string>
</publisherId>
<volume>134</volume>
<issue>2</issue>
<pages><first>144</first>
<last>149</last>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<namedEntities><unitex><date><json:string>1976</json:string>
<json:string>1972</json:string>
</date>
<geogName></geogName>
<orgName><json:string>Children's Hospital Medical Center, Boston, Massachusetts Peter F</json:string>
<json:string>Children's Hospital Medical Center</json:string>
<json:string>Laboratory of Infectious Diseases, National Institutes of Health, Bethesda, Md</json:string>
<json:string>Children's Hospital Medical Center Pharmacy</json:string>
<json:string>National Institute of Allergy and Infectious Diseases</json:string>
<json:string>Division of Infectious Diseases</json:string>
<json:string>Department of Medicine</json:string>
<json:string>Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, Tennessee</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>Peter F. Wright</json:string>
<json:string>Robert Gilfillin</json:string>
<json:string>Marvin Paulshock</json:string>
<json:string>Hong Kong</json:string>
<json:string>Sheldon Aronson</json:string>
<json:string>The</json:string>
</persName>
<placeName><json:string>United States</json:string>
<json:string>Wilmington</json:string>
<json:string>Boston</json:string>
<json:string>Japan</json:string>
<json:string>Del.</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl><json:string>[12]</json:string>
<json:string>[2-4]</json:string>
<json:string>[6]</json:string>
<json:string>[11]</json:string>
<json:string>[8]</json:string>
<json:string>[1]</json:string>
<json:string>[4, 6]</json:string>
<json:string>[10]</json:string>
<json:string>[5]</json:string>
<json:string>[15]</json:string>
<json:string>[7]</json:string>
<json:string>Biandrate et al. [9]</json:string>
<json:string>[13]</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/HXZ-1P46HZCW-3</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - microbiology</json:string>
<json:string>2 - infectious diseases</json:string>
<json:string>2 - immunology</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - biomedical research</json:string>
<json:string>3 - microbiology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Infectious Diseases</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Immunology and Allergy</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
</inist>
</categories>
<publicationDate>1976</publicationDate>
<copyrightDate>1976</copyrightDate>
<doi><json:string>10.1093/infdis/134.2.144</json:string>
</doi>
<id>EF87B5B5A17FF4F98612144AC67755E0B07EB3ED</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1P46HZCW-3/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1P46HZCW-3/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-1P46HZCW-3/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis</title>
<respStmt><resp>Références bibliographiques récupérées via GROBID</resp>
<name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name>
</respStmt>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>The University of Chicago Press</publisher>
<availability><licence>© 1976 by the University of Chicago</licence>
</availability>
<date type="Copyright" when="1976">1976</date>
<date when="1976-08">1976</date>
</publicationStmt>
<notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note>
<note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis</title>
<author xml:id="author-0000" role="corresp"><persName><surname>Wright</surname>
<forename type="first">Peter F.</forename>
</persName>
<affiliation><orgName type="department">From the Department of Medicine and the Division of Infectious Diseases</orgName>
<orgName type="institution">Children's Hospital Medical Center</orgName>
<address><addrLine>Boston, Massachusetts</addrLine>
</address>
</affiliation>
<affiliation role="corresp">Please address requests for reprints to Dr. Peter F. Wright, Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, Tennessee 37203.</affiliation>
</author>
<author xml:id="author-0001"><persName><surname>Khaw</surname>
<forename type="first">Kon Taik</forename>
</persName>
<affiliation><orgName type="department">From the Department of Medicine and the Division of Infectious Diseases</orgName>
<orgName type="institution">Children's Hospital Medical Center</orgName>
<address><addrLine>Boston, Massachusetts</addrLine>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><surname>Oxman</surname>
<forename type="first">Michael N.</forename>
</persName>
<affiliation><orgName type="department">From the Department of Medicine and the Division of Infectious Diseases</orgName>
<orgName type="institution">Children's Hospital Medical Center</orgName>
<address><addrLine>Boston, Massachusetts</addrLine>
</address>
</affiliation>
</author>
<author xml:id="author-0003"><persName><surname>Harry</surname>
<forename type="first">Shwachman</forename>
</persName>
<affiliation><orgName type="department">From the Department of Medicine and the Division of Infectious Diseases</orgName>
<orgName type="institution">Children's Hospital Medical Center</orgName>
<address><addrLine>Boston, Massachusetts</addrLine>
</address>
</affiliation>
</author>
<idno type="istex">EF87B5B5A17FF4F98612144AC67755E0B07EB3ED</idno>
<idno type="ark">ark:/67375/HXZ-1P46HZCW-3</idno>
<idno type="DOI">10.1093/infdis/134.2.144</idno>
</analytic>
<monogr><title level="j" type="main">Journal of Infectious Diseases</title>
<title level="j" type="abbrev">J Infect Dis.</title>
<idno type="hwp">jinfdis</idno>
<idno type="publisher-id">jid</idno>
<idno type="pISSN">0022-1899</idno>
<idno type="eISSN">1537-6613</idno>
<imprint><publisher>The University of Chicago Press</publisher>
<date when="1976-08">1976</date>
<biblScope unit="vol">134</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="144">144</biblScope>
<biblScope unit="page" to="149">149</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-09"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
                        <ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><abstract><p>Amantadine·Hel, an antiviral drug clinically effective against most strains of influenza A virus, was evaluated in a double-blind trial in 153 children with cystic fibrosis during the initial appearance of influenza A/ England/ 42 virus in the New England area. Infection with this variant strain of influenza virus did not reach epidemic proportions during the study, so that the effectiveness of amantadine in this study population could not be fully assessed. However, the potential symptomatic and biochemical toxicity of amantadine was carefully monitored in a pediatric population. Serologic screening by complement fixation tests indicated that respiratory viruses may be important pathogens in exacerbations of respiratory disease in patients with cystic fibrosis.</p>
</abstract>
<textClass ana="subject"><keywords scheme="heading"><term>Major Articles</term>
</keywords>
</textClass>
<langUsage><language ident="EN"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2019-12-09" who="#istex" xml:id="pub2tei">formatting</change>
<change xml:id="refBibs-istex" who="#ISTEX-API" when="2019-12-10">References added</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1P46HZCW-3/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType>
<istex:document><article article-type="research-article">

<front>

<journal-meta>

<journal-id journal-id-type="hwp">jinfdis</journal-id>

<journal-id journal-id-type="publisher-id">jid</journal-id>

<journal-title>Journal of Infectious Diseases</journal-title>

<abbrev-journal-title>J Infect Dis.</abbrev-journal-title>

<issn pub-type="ppub">0022-1899</issn>

<issn pub-type="epub">1537-6613</issn>

<publisher>

<publisher-name>The University of Chicago Press</publisher-name>

</publisher>

</journal-meta>

<article-meta>

<article-id pub-id-type="doi">10.1093/infdis/134.2.144</article-id>

<article-categories>

<subj-group subj-group-type="heading">

<subject>Major Articles</subject>

</subj-group>

</article-categories>

<title-group>

<article-title>Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis</article-title>

</title-group>

<contrib-group>

<contrib contrib-type="author" corresp="yes">

<name><surname>Wright</surname>

<given-names>Peter F.</given-names>

</name>
<xref ref-type="corresp" rid="cor1"></xref>

</contrib>

<contrib contrib-type="author">

<name><surname>Khaw</surname>

<given-names>Kon Taik</given-names>

</name>

</contrib>

<contrib contrib-type="author">

<name><surname>Oxman</surname>

<given-names>Michael N.</given-names>

</name>

</contrib>

<contrib contrib-type="author">

<name><surname>Harry</surname>

<given-names>Shwachman</given-names>

</name>

</contrib>

<aff><institution>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center</institution>
, <addr-line>Boston, Massachusetts</addr-line>
</aff>

</contrib-group>

<author-notes>

<corresp id="cor1">Please address requests for reprints to Dr. Peter F. Wright, Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, Tennessee 37203.</corresp>

</author-notes>

<pub-date pub-type="ppub">

<month>8</month>

<year>1976</year>

</pub-date>

<volume>134</volume>

<issue>2</issue>

<fpage>144</fpage>

<lpage>149</lpage>

<history>

<date date-type="received">

<day>6</day>

<month>11</month>

<year>1975</year>

</date>

<date date-type="rev-recd">

<day>24</day>

<month>2</month>

<year>1976</year>

</date>

</history>

<copyright-statement>© 1976 by the University of Chicago</copyright-statement>

<copyright-year>1976</copyright-year>

<abstract>

<p>Amantadine·Hel, an antiviral drug clinically effective against most strains of influenza A virus, was evaluated in a double-blind trial in 153 children with cystic fibrosis during the initial appearance of influenza A/ England/ 42 virus in the New England area. Infection with this variant strain of influenza virus did not reach epidemic proportions during the study, so that the effectiveness of amantadine in this study population could not be fully assessed. However, the potential symptomatic and biochemical toxicity of amantadine was carefully monitored in a pediatric population. Serologic screening by complement fixation tests indicated that respiratory viruses may be important pathogens in exacerbations of respiratory disease in patients with cystic fibrosis.</p>

</abstract>

</article-meta>

</front>

</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo><title>Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA"><title>Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis</title>
</titleInfo>
<name type="personal" displayLabel="corresp"><namePart type="given">Peter F.</namePart>
<namePart type="family">Wright</namePart>
<affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</affiliation>
<affiliation>Please address requests for reprints to Dr. Peter F. Wright, Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, Tennessee 37203.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Kon Taik</namePart>
<namePart type="family">Khaw</namePart>
<affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Michael N.</namePart>
<namePart type="family">Oxman</namePart>
<affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Shwachman</namePart>
<namePart type="family">Harry</namePart>
<affiliation>From the Department of Medicine and the Division of Infectious Diseases, Children's Hospital Medical Center, Boston, Massachusetts</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre>
<originInfo><publisher>The University of Chicago Press</publisher>
<dateIssued encoding="w3cdtf">1976-08</dateIssued>
<copyrightDate encoding="w3cdtf">1976</copyrightDate>
</originInfo>
<abstract>Amantadine·Hel, an antiviral drug clinically effective against most strains of influenza A virus, was evaluated in a double-blind trial in 153 children with cystic fibrosis during the initial appearance of influenza A/ England/ 42 virus in the New England area. Infection with this variant strain of influenza virus did not reach epidemic proportions during the study, so that the effectiveness of amantadine in this study population could not be fully assessed. However, the potential symptomatic and biochemical toxicity of amantadine was carefully monitored in a pediatric population. Serologic screening by complement fixation tests indicated that respiratory viruses may be important pathogens in exacerbations of respiratory disease in patients with cystic fibrosis.</abstract>
<note type="author-notes">Please address requests for reprints to Dr. Peter F. Wright, Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, Tennessee 37203.</note>
<relatedItem type="host"><titleInfo><title>Journal of Infectious Diseases</title>
</titleInfo>
<titleInfo type="abbreviated"><title>J Infect Dis.</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">0022-1899</identifier>
<identifier type="eISSN">1537-6613</identifier>
<identifier type="PublisherID">jid</identifier>
<identifier type="PublisherID-hwp">jinfdis</identifier>
<part><date>1976</date>
<detail type="volume"><caption>vol.</caption>
<number>134</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>2</number>
</detail>
<extent unit="pages"><start>144</start>
<end>149</end>
</extent>
</part>
</relatedItem>
<identifier type="istex">EF87B5B5A17FF4F98612144AC67755E0B07EB3ED</identifier>
<identifier type="ark">ark:/67375/HXZ-1P46HZCW-3</identifier>
<identifier type="DOI">10.1093/infdis/134.2.144</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© 1976 by the University of Chicago</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource>
<recordOrigin>Converted from  (version 1.2.0) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2019-12-09</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1P46HZCW-3/record.json</uri>
</json:item>
</metadata>
<covers><json:item><extension>tiff</extension>
<original>true</original>
<mimetype>image/tiff</mimetype>
<uri>https://api.istex.fr/document/EF87B5B5A17FF4F98612144AC67755E0B07EB3ED/covers/tiff</uri>
</json:item>
</covers>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001264 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001264 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:EF87B5B5A17FF4F98612144AC67755E0B07EB3ED
   |texte=   Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis

Evaluation of the Safety of Amantadine. HCI and the Role of Respiratory Viral Infections in Children with Cystic Fibrosis

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri